Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
19.96
-0.15 (-0.75%)
At close: Dec 5, 2025, 4:00 PM EST
19.70
-0.26 (-1.30%)
After-hours: Dec 5, 2025, 7:26 PM EST
Denali Therapeutics Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Denali Therapeutics stock ranges from a low of $26 to a high of $42. The average analyst price target of $32.67 forecasts a 63.68% increase in the stock price over the next year.
Price Target: $32.67 (+63.68%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 6 | 7 |
| Buy | 7 | 7 | 8 | 8 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 16 | 16 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $30 → $31 | Buy | Maintains | $30 → $31 | +55.31% | Dec 5, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +60.32% | Dec 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $24 → $26 | Buy | Maintains | $24 → $26 | +30.26% | Nov 4, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 8, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $33 → $30 | Buy | Maintains | $33 → $30 | +50.30% | Aug 18, 2025 |
Financial Forecast
Revenue This Year
1.09M
Revenue Next Year
44.74M
from 1.09M
Increased by 3,993.60%
EPS This Year
-3.03
from -2.57
EPS Next Year
-3.08
from -3.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 15.8M | 167.8M | ||||
| Avg | 1.1M | 44.7M | ||||
| Low | n/a | 7.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 15,251.3% | ||||
| Avg | - | 3,993.6% | ||||
| Low | - | 537.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.71 | -2.09 | ||||
| Avg | -3.03 | -3.08 | ||||
| Low | -3.08 | -3.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.